Stake on transfer: evolution of a regulatory framework for the development of the pharmaceutical industry
- Authors: Rudko A.I.1, Konikov D.L.2, Sidorov K.O.2, Ilyinova J.G.2
-
Affiliations:
- OOO «NOVAMEDIKA INNOTECH»
- Saint Petersburg State Chemopharmaceutical University
- Issue: Vol 69, No 7 (2020)
- Pages: 5-9
- Section: Articles
- URL: https://journals.eco-vector.com/0367-3014/article/view/113394
- DOI: https://doi.org/10.29296/25419218-2020-07-01
- ID: 113394
Cite item
Abstract
Drug technology transfer is one of the ways to provide the country's population with affordable and effective drugs. The development of the pharmaceutical industry and government initiatives aimed at modernizing healthcare make Russia attractive to international pharmaceutical business, which in turn allows the Russian pharmaceutical industry to obtain modern world-class technologies and equipment, high-tech jobs, and production management methods and enables partners to have a guaranteed sales market. However, despite the importance and priority of drug technology transfer, foreign manufacturers face a variety of economic and legal problems when making strategic decisions on technology transfer. The development of high-tech production of medicines is associated with the technology transfer process. The above process arises from the transition from one stage of the drug life cycle to the next one. The important feature characterizing the transfer process is the regulation of the transfer of knowledge and technologies, which should ensure the stable safety of a drug and its efficacy, and the reproducibility of quality control methods, by taking into account the results of industrial production. The above aspects of drug circulation are laid down at the stage of development. The specificity of the pharmaceutical industry lies in the need to develop technologies in the context of market globalization and intense competition in drug development, production, and sales. In this connection, the export opportunities of states come to the fore, the important part of which is the convenience of registering and launching modern, effective, safe and competitive drugs in terms of price on the international market.
Keywords
Full Text
About the authors
Alexander I. Rudko
OOO «NOVAMEDIKA INNOTECH»
Email: rudkoa@inbox.ru
Director General
Dmitry L. Konikov
Saint Petersburg State Chemopharmaceutical University
Email: kdl68@mail.ru
Master's student, f
Kirill O. Sidorov
Saint Petersburg State Chemopharmaceutical UniversityResearcher of the Department of scientific research
Julia G. Ilyinova
Saint Petersburg State Chemopharmaceutical University
Email: yulia.ilynova@pharminnotech.com
Vice-rector for academic affairs
References
- Правительство РФ, Постановление от 15 апреля 2014 г. №305 «Об утверждении государственной программы Российской Федерации «Развитие фармацевтической и медицинской промышленности».
- Наркевич И.А., Умаров С.З. Технологическая модернизация процессов лекарственного обеспечения в лечебно-профилактических учреждениях. Менеджер здравоохранения. 2013; 1: 44-9.
- Информационный портал «Новости GMP». Режим доступа: https://gmpnews.ru (дата обращения: 10.12.2019).
- Постановление Правительства РФ от 30 ноября 2015 гг. №1289 «Об установлении ограничений доступа иностранных лекарственных препаратов при государственных закупках».
- Приказ Министерства финансов от 4 июня 2018 г. №126н «Об условиях допуска товаров, происходящих из иностранного государства или группы иностранных государств, для целей осуществления закупок для обеспечения государственных и муниципальных нужд».
- WHO guidelines on Transfer of Technology in pharmaceutical manufacturing №961. 2011; (7): 286-309.
- ISPE «Good Practice Guide: Technology Transfer. Third Edition»
- Государственная фармакопея XIV издания. Том I. [Электронное издание]. Режим доступа: http://resource.rucml. ru/feml/pharmacopia/14_1/HTML/207/index.html (дата обращения: 10.12.2019).